Search - tctmd.com

Displaying 81 - 100 of 106

Sort: Relevancy | Date

News Daily News

Study Explores Possible Mechanism to Explain Air Pollution-CVD Link

Todd Neale

October 27, 2016

News Daily News

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Michael O'Riordan

August 12, 2016

News Daily News

Omega-3 Fatty Acids Can Aid Cardiac Remodeling After Acute MI

Leah Lawrence

August 02, 2016

News Daily News

Even With No Restrictions on Fat Intake, Mediterranean Diet May Help Prevent Disease

Michael H. Wilson

July 19, 2016

News Daily News

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Michael O'Riordan

March 09, 2016

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Michael O'Riordan

March 07, 2016

News Daily News

一项观察性研究表明，患者在急性心肌梗死后服用PUFA可真正受益

November 30, 2015

News Daily News

Un Estudio Observacional Revela los Beneficios Reales de Pacientes a Tratamiento con AGPI Post-IAM

November 30, 2015

News Daily News

Observational Study Hints at Real Benefits for Patients Who Take PUFAs After Acute MI

November 30, 2015

News Industry News

Doctor's Best Introduces Two New Heart Health Supplements

August 11, 2015

News Industry News

First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100

June 04, 2015

News Industry News

Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

September 16, 2014

News Industry News

Boston Scientific Receives FDA Approval for REBEL™ Platinum Chromium Coronary Stent System

July 21, 2014

News Industry News

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

June 11, 2014

News Industry News

US FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridaemia

May 06, 2014

News Industry News

Boston Scientific Receives CE Mark Approval for REBEL™ Platinum Chromium Coronary Stent System

March 12, 2014

News Daily News

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

February 25, 2013

News Daily News

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

February 25, 2013

News Industry News

Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS Element™ Plus Platinum Chromium Stent System

June 04, 2012

Advertisement

Study Explores Possible Mechanism to Explain Air Pollution-CVD Link

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Omega-3 Fatty Acids Can Aid Cardiac Remodeling After Acute MI

Even With No Restrictions on Fat Intake, Mediterranean Diet May Help Prevent Disease

¿Relaja el Acuerdo de la FDA con Amarin el Control de las Promociones Fuera de Indicación?

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

一项观察性研究表明，患者在急性心肌梗死后服用PUFA可真正受益

Un Estudio Observacional Revela los Beneficios Reales de Pacientes a Tratamiento con AGPI Post-IAM

Observational Study Hints at Real Benefits for Patients Who Take PUFAs After Acute MI

Doctor's Best Introduces Two New Heart Health Supplements

First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100

Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

Boston Scientific Receives FDA Approval for REBEL™ Platinum Chromium Coronary Stent System

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

US FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridaemia

Boston Scientific Receives CE Mark Approval for REBEL™ Platinum Chromium Coronary Stent System

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS Element™ Plus Platinum Chromium Stent System

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content